Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, along with scientists from the Broad Institute of MIT and Harvard, will present advancements related to TfR1 CapX™. A leading...
Cellenkos®, Inc., a clinical-stage biotechnology company, developing allogeneic, tissue-targeted regulatory T cell (Treg) therapies, today announced the receipt of U.S. Food and Drug Administration (FDA) clearance to initiate CK0801 Phase 2...
Ascletis Pharma Inc. announces completion of enrollment in its 13-week U.S. Phase II study (NCT07321678) evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist, for the treatment of type 2 diabetes mellitus (T2D). T2D is the...
Orthogon Therapeutics announced the closing of a follow-on $11 million financing, bringing its total capital raised to $36 million. This financing supports the continued advancement of its first-in-class drug against BK polyomavirus. BK virus...
Baxter International Inc. a global medtech leader, is highlighting recent additions to its Global Surgical Solutions and Patient Support Systems portfolios, as well as its broad Advanced Surgery portfolio of hemostatic and sealing agents. New...
Eton Pharmaceuticals, Inc an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced it has in-licensed U.S. commercialization rights to HEMANGEOL® oral solution from Pierre Fabre...
US-Rx Care, the nation's first fiduciary pharmacy risk manager and an industry leader since 2007, is issuing an urgent strategic call-out to employers: the Pharmacy Benefit Manager (PBM) industry has reached a point of no return. After years of...
Merck known as MSD outside of the United States and Canada, and Eisai today announced the first presentation of results from the Phase 3 LITESPARK-011 trial evaluating the dual oral regimen of WELIREG® (belzutifan). Merck’s first-in-class oral...
Neurizon® Therapeutics Limited a clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce that the first participant has been dosed in Regimen I of the HEALEY ALS...
Clarity Pharmaceuticals a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that yet another participant with mCRPC in the...
PureTech Health plc a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, announced that the U.S. Food and Drug Administration (FDA) and European Commission have granted Orphan Drug...
P-Cure, a supplier of compact, gantry-less proton therapy systems, announced the first-ever prospective clinical results demonstrating the feasibility, safety, and early efficacy of gantry-less upright proton therapy for lung cancer...
IRBM, a leader in early drug discovery research, has announced a major scientific breakthrough with the discovery of a novel and potent allosteric inhibitor targeting the Zika virus (ZIKV) protease (NS2B-NS3). The findings, published in Nature...
A newly published scientific paper titled "Gene Expression Patterns in Lung Adenocarcinoma Cells in Response to Changes in Deuterium Concentration" (Csonka, G.I.; Papp, A.; Somlyai, I.; Somlyai, G. Gene Expression Patterns in Lung Adenocarcinoma...
Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for the treatment of chronic hepatitis D virus infection in adults with or without compensated...
Alamar Biosciences, Inc. a leader in precision proteomics dedicated to advancing the early detection of disease, is proud to announce the launch of its Research Use Only (RUO) NULISAqpcr™ AD 5-plex Assay. This innovative solution enables...
Clover Biopharmaceuticals, Ltd. a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. Announced that enrollment of the first participants has...
Shanghai Ark Biopharmaceutical Co., Ltd. announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate Chloride and Dexmethylphenidate Hydrochloride Capsules (Aizhida) for...
Coya Therapeutics, Inc. a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced positive results of an investigator-initiated...
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal...